News
DXCM
80.04
+5.57%
4.22
Nasdaq 100 Movers: ODFL, DXCM
NASDAQ · 22h ago
DexCom, Insulet, Tandem benefit from Novo Nordisk CagriSema data
Seeking Alpha · 23h ago
BUZZ-U.S. STOCKS ON THE MOVE-Mission Produce, Sirius XM, Carnival Corp
Reuters · 1d ago
Early notable gainers among liquid option names on December 20th
TipRanks · 1d ago
2025 Picks: 2 Stocks to Buy Now for 50% Upside
Barchart · 1d ago
Oura boosts valuation to $5.2B in latest funding round
Seeking Alpha · 2d ago
DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
NASDAQ · 3d ago
Insiders At DexCom Sold US$18m In Stock, Alluding To Potential Weakness
Simply Wall St · 3d ago
Gabelli Small Cap Growth Fund Q3 2024 Commentary
Seeking Alpha · 3d ago
Alger Mid Cap Growth Fund Q3 2024 Commentary
Seeking Alpha · 3d ago
Dexcom Launched Proprietary Generative AI Platform To Integrate GenAI Into Glucose Biosensing
Benzinga · 4d ago
DEXCOM LAUNCHES THE FIRST GENERATIVE AI PLATFORM IN GLUCOSE BIOSENSING
Reuters · 4d ago
DEXCOM - ALBERTA GOVERNMENT EXPANDS DEXCOM G7 CGM ELIGIBILITY TO ADULTS 18+
Reuters · 4d ago
ALBERTA GOVERNMENT LIFTS AGE RESTRICTIONS ON CONTINUOUS GLUCOSE MONITORS (CGM) AND ELIGIBLE ALBERTANS WITH TYPE 1 OR TYPE 2 DIABETES CAN NOW ACCESS DEXCOM G7 CGM
Reuters · 4d ago
Harbor Health Care ETF Q3 2024 Commentary
Seeking Alpha · 4d ago
Worst performing stocks for tax loss selling – Wolfe
Seeking Alpha · 4d ago
American Century Ultra Fund Q3 2024 Commentary
Seeking Alpha · 4d ago
Peering Into DexCom's Recent Short Interest
Benzinga · 4d ago
American Century Sustainable Equity Fund Q3 2024 Commentary
Seeking Alpha · 5d ago
Pioneer Select Mid Cap Growth Fund Q3 2024 Performance And Market Commentary
Seeking Alpha · 5d ago
More
Webull provides a variety of real-time DXCM stock news. You can receive the latest news about Dexcom Inc through multiple platforms. This information may help you make smarter investment decisions.
About DXCM
DexCom, Inc. is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.